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Abstract
Background: Rotavirus is acknowledged as an important cause of paediatric gastroenteritis worldwide. In Spain,
comprehensive data on the burden of rotavirus disease was lacking.
Methods: A prospective, multicenter, observational study was carried out, during the winter season, from October
to April 2014 in selected areas of Spain (Catalonia, Basque Country, Andalusia) to estimate the frequency and
characteristics of acute gastroenteritis (AGE) and rotavirus gastroenteritis (RVGE) in children ≤3 years of age seeking
medical care in primary care and emergency department centres.
Results: Of the 1087 episodes of AGE registered, 33.89 % were RVGE positive. The estimated incidence of RVGE,
was 40.3 (95 % CI 36.1–44.8) episodes per 10,000 child-months in children ≤ 3 years of age and the 5-month
(December-April) seasonal RVGE incidence rate was 2.01 [1.81–2.24] per 100 children. No vaccination and attending
a day care centre were the main risk factors for RV infection. RVGE infected children presented more frequently
with fever (63.9 % vs. 45.1 %, p = 0.009), vomiting (61.2 % vs. 44.3 %, p = 0.015), suffered more dehydration, and
were hospitalised and went to the emergency room more often (41.7 % vs. 15.7 %, p <0.001) than non-RVGE
infected ones. Children were usually more tired (77.5 % vs. 54.2 %, p <0.001), tearful, (47.2 % vs. 34.8 %, p <0.001),
and easily irritated (76.5 % vs. 59.8 %, p <0.001), and parents were more concerned (41.7 % vs. 15.7 %, p <0.001)
and suffered more working rhythm disturbances (39.0 % vs. 22.9 %, p <0.001). The cost for families of RVGE cases
was significantly higher than the cost of non-RVGE infected ones (47.3 vs 36.7 euros, p = 0.011). Vaccinated children
suffered less clinical symptoms and no hospitalization. Therefore, vaccination decreases the psychosocial stressors
caused by the disease in the family.
Conclusions: Rotavirus infections are responsible for a substantial proportion of AGE cases in children ≤3 years of
age in Spain attended at primary care visits. RVGE episodes are associated with greater clinical severity, greater
alterations in the child´s behaviour, and higher parental distress. The outcomes of the present study recommend
that routine rotavirus vaccination in infants ≤3 years of age could considerably reduce the serious burden of this
potentially serious childhood disease.
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Background
Acute gastroenteritis (AGE) is responsible for an import-
ant morbidity and mortality in children worldwide. Rota-
virus infection is the leading cause of AGE [1] and is
more frequently associated with severe presentation and
increased hospitalization rates, compared with AGE due
to other infectious causes [2]. Rotavirus is highly conta-
gious, and in temperate climates usually peaks in the
course of the winter months [3]. Specifically, in Spain, it
has been described that the RVGE season occurs be-
tween December and April, with the higher incidence
observed between January and March [4–6].
The estimated annual rate of clinical rotavirus gastro-
enteritis (RVGE) is 1 case in every 7 children within the
European Union, giving rise to 231 deaths, more than
87,000 hospitalisations, and nearly 700,000 outpatient
visits [4]. AGE caused by rotavirus is characterized by
watery diarrhoea; with a mean duration of 2–7 days that
can lead to severe dehydration requiring hospital treat-
ment and, in some cases, be fatal. It has been estimated
that, in Europe, 1 out of 54 RVGE will require hospital
admission [7].
RVGE is also related to a significant economic burden
for the health care system (medical visits, hospitaliza-
tions, treatment costs) and for families (parent work
days lost, costs related childcare, etc.) [8, 9]. Taking all
these into account, rotavirus infections have been classi-
fied as an essential target for vaccination. Moreover, the
guidelines published by the European Society for Paedi-
atric Infectious Diseases and the European Society for
Paediatric Gastroenterology, Hepatology, and Nutrition
[10, 11], as well as by the WHO Strategic Advisory
Group of Experts [12] recommend vaccination against
rotavirus. Rotavirus vaccines available, a live attenuated
monovalent human vaccine (GSK Biologicals) [13] and a
live human-bovine reassortant vaccine (Sanofi Pasteur
MSD) [14] have demonstrated high efficacy, effectiveness
and a good safety profile both in pre-licensure clinical
trials and in post-authorization studies [15]. Rotavirus
vaccines were introduced in Spain in 2006–2007 but
they are not publicly funded by the Spanish National
Health Care System although they are recommended by
the Spanish Association of Paediatricians and prescribed
by paediatricians. Disease burden data generated from
epidemiological studies are important for making deci-
sions related to vaccine recommendations at a national
level and to enable the monitoring of vaccine impact.
The main objective of the study was to estimate the
frequency and characteristics of RVGE and non-RVGE
in children from 0 to 3 years of age attended at primary
care and emergency department centres in Spain. Other
objectives included to determine the clinical symptoms
and consequences of both types of GE and to assess the
impact of RVGE on affected children and their parents.
Methods
Study design
A prospective, multicenter, observational study was car-
ried out during the 2014 winter season (December-
April) in 3 specific areas of Spain (Catalonia, Basque
Country, Andalusia) to evaluate the frequency of acute
gastroenteritis (AGE) and rotavirus gastroenteritis
(RVGE) in children from 0 to 3 years of age attended at
primary care and emergency department centres.
Setting
To conduct the study three principal investigators, one
for each Autonomous Community, were selected on the
basis of their experience as clinical paediatricians and re-
searchers engaged in the management of children with
RVGE. These principal investigators were involved in
the pre-selection of a convenience sample of a total of
87 paediatricians whose current practice included the
management of children with RVGE (24 in Andalusia,
34 in Catalonia, and 29 in the Basque Country), of which
only 64 finally participated in the recruitment (15 in
Andalusia, 22 in Catalonia, and 27 in the Basque Coun-
try). Participant paediatricians, who recruited patients,
belong to a total of 33 centres (Andalusia 9, Catalonia 8,
and 16 from the Basque Country). Of these, 31 centres
and 54 paediatricians were primary care practices, and 2
were emergency services centres, namely the Virgen de
Valme Hospital (Andalusia) and the University Hospital
of Basurto (Basque Country). The study was carried out
based on the 2004 amendment of the Helsinki Declar-
ation, the Guidelines for Good Epidemiological Practice
[16], as well as with the local regulatory requirements.
The local ethics committee approved the protocol in
each area of study (Comité Ético de Investigación Clínica
del l’IDIAP Jordi Gol i Gurina, Comité Ético del Hospital
Universitario Virgen del Rocío, Comité de Ética del País
Vasco)
Type of participants
All children ≤3 years of age, residing within a specific
study area during the study period and who were seek-
ing medical intervention for AGE qualified for inclusion
in the study. AGE was described as an episode of at least
3 loose or watery stools, and/or vomiting associated with
gastroenteritis occurring within a 24-h period in the
7 days prior to the medical visit [17].
Those children who had a previously diagnosed
chronic disease of the gastrointestinal tract for which
symptoms were compatible with the definition of AGE
were not considered eligible for inclusion. In the Basque
Country and in accordance with the suggestion of the
local ethics committee; children with mucus and bloody
stools were also excluded.
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Eligible children whose parents did not provide writ-
ten, informed consent were listed as “not included eli-
gible children”. Data on these children were filed
anonymously on a “screening list” that showed only data
related to their age and consultation date. This screening
list was utilized in the calculations of estimates
(incidence).
Sample size calculations
The sample size was estimated after stratifying by Au-
tonomous Communities (AC). At each AC, the total
sample size was calculated on the basis of the number
needed to obtain an incidence rate of acute gastrointes-
tinal episodes due to rotavirus between 3.7–9.2 %, as re-
ported in the study REVEAL, with a precision of 95 %
and an error of 2–3 % around the estimate. For obtain-
ing this sample, as only 8–12 % gastro-intestinal epi-
sodes among children of age corresponding to the study
population result in a demand for clinical attention
(7.5–10.3 % at primary care paediatricians, 0.2–1.5 % at
the emergency room), a total of 350 gastrointestinal epi-
sodes per AC was estimated. For obtaining this number
of episodes among the study population at each AC, the
rate of children of age corresponding to the study popu-
lation per paediatrician and hospital catchment areas at
each AC was estimated in order to include as many pae-
diatricians as needed among the recruiters.
Data collection
Children who met the inclusion criteria and whose par-
ents signed the informed consent were included con-
secutively. After informed consent was obtained, the
study paediatrician examined each patient and com-
pleted a standardized data collection form (DCF) that
included the demographic data, environmental factors
(breastfeeding, attendance at day care centres, etc), in-
formation on clinical symptoms, and illness onset.
One stool sample was collected for rotavirus testing
(VIKIA Rota-Adeno immuno-chromatographic test (bio-
Mérieux)® from each child (sensitivity = 96.6 %, specificity =
92.9 %) [18]. If no stool sample was obtained during the
baseline visit, parents were requested to collect a stool sam-
ple and bring it into the health care center within four days.
Children with a positive VIKIA Rota-Adeno immuno-
chromatographic test result for rotavirus were classified as
RVGE positive (RV+).
To evaluate the characteristics of the episode, parents of
each included child were given a diary and were then asked
to complete the questionnaire at home until the episode
was resolved and to return the completed diary to their
paediatrician (Additional file 1: Table S1). During a follow-
up visit or phone call, the paediatrician followed-up on
whether or not the diary had been completed and returned,
and then collected the data in the DCF.
Data collected in the DCF included demographic data
(age, gender), environmental factors, date of the AGE
onset, rotavirus vaccination, VIKIA Rota-Adeno immuno-
chromatographic test result (bioMérieux)® in faeces, clin-
ical presentation of the AGE in the last 24 h (diarrhoea,
fever, vomiting, dehydration), consequences of infection
(referral of patient to the emergency room and/or
hospitalization), treatment received for the infection, AGE
symptoms, duration of episode, contact with health ser-
vices, disease severity (level of dehydration), family mem-
bers with similar symptoms, work missed by the parents,
and additional costs for parents related to the episode.
The data collected by researchers in the DCF was inte-
grated into a centralized database that was used for the
analysis of results.
Main variables analyzed
The RVGE episode frequency has been described for the
whole sample of patients registered in the study.
Monthly incidence rates (IR) per 10,000 children ≤
3 years of age and 5-month IR per 100 children ≤3 years
of age have been calculated from cases for which the in-
vestigators’ patient quotas were available (Catalonia and
Basque Country).
For the sample of patients who consented to partici-
pate in the study, patient characteristics and clinical fea-
tures have been described including socio-demographic
characteristics, environmental factors, clinical data,
characterization of AGE, and consequences of the AGE.
Statistical analyses
Definition of data sets to be analyzed
The reference population used to estimate the incidence
values corresponds to the number of children between 0
and 3 years as part of the quotas of the participating re-
searchers (17,696 children). The eligible population is
composed of children who suffered an episode of AGE
during the study period and who met the inclusion cri-
teria (1,108 children). The preselected sample is the eli-
gible population who gave their informed consent to
participate (515 children). The recruited sample consists
of subjects that make up the population of pre-selection
and that had the DCF and the patient diary filled out
(471 patients). The sample per protocol analysis is that
part of the preselected sample that effectively meets the
inclusion criteria (456 patients) (Fig. 1 and Additional
file 2: Figure S1). A description was made and an infer-
ential analysis comparing between confirmed cases of
rotavirus infection with other subjects with AGE not
caused by rotavirus was performed in this population.
Statistical methods
Qualitative data were described with frequency tables
and percentages; and quantitative data with quantitative
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descriptive statistics (mean, standard deviation (SD), me-
dian, and range values). Incidence has been expressed as
monthly incidence rate (per 10,000 children) and a sea-
sonal rotavirus IR (per 100 children). Incidence rates
were obtained considering daily RVGE incidence (daily
cases of RVGE confirmed/person-time (days) at risk)
and the total number of days in the follow-up. Poisson
distribution was used to calculate 95 % CI.
The different variables of interest were compared be-
tween both groups of study (RVGE+/RVGE-) using the
Chi-squared or the Fisher’s exact test for categorical var-
iables, and the Student’s “t” test for independent data or
the Mann-Whitney U test in the event that the assump-
tion of normality was not met, to compare quantitative
variables. The Kolmogorov-Smirnov test was used to as-
sess if quantitative variables followed a normal distribu-
tion. Statistical analyses were performed using SAS
software (version 9.2; SAS Institute). Statistical signifi-
cance was set at p < 0.05.
A univariate analysis was performed based on the re-
sults obtained from the VIKIA test carried out on the
sample population recruited in accordance with the vari-
ables included in the prospective study. Then, for those
variables where a significant association was detected, a
multivariate analysis was carried out to describe the pro-
file differential in those patients with RVGE compared
to those with AGE. A logistic regression analysis was
used to compare the profiles between RVGE and non-
rotavirus AGE patients. The results of the adjustments
made to these models have been described using an
odds ratio (OR), its 95 % confidence interval (CI) and
the corresponding p values obtained.
Results
During the 5-month study period (December-April),
1,087 episodes of AGE were registered and of them 471
gave their consent to participate in the study. Finally,
456 patients were recruited with a clinical episode of
Total population
N=17696+AND
Elegible population
N=1108*
Pre-selection population
N=515
Recruited sample
N=471
Analysis sample
N=456
51 unsigned consent form
31 due to lack of time of the researcher
147 due to other motives /reasons
364 unknown
44 incomplete CDR
15 cases invalid for analysis
Patient
Quota
Patient 
Register
CDR 
Database
1
2
3
4
Patients who met inclusion criteria, except criteria 12 (signed consent form), but not exclusion criteria.
Signed consent form (Met inclusion criteria #12)
Completed CDR+ patient diary
Patients who met inclusion criteria, but not the exclusion criteria (verify criteria).
* One patient register was lost in Andalusia. These patients could not be included.
1
2
3
4
1
2
3
4
Fig. 1 Flow-chart of the study
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AGE (15 cases were invalid): 107 (23.4 %) from
Andalusia, 138 (30.3 %) from Catalonia and 211 (46.3 %)
from the Basque Country.
Frequency and incidence of AGE and RVGE
Of the 1,087 episodes of AGE registered, 33.89 % were
RVGE positive (Fig. 2). The great majority of AGE epi-
sodes occurred during the months of January and Febru-
ary (60.3 % of all cases). During these months, the
proportion of RVGE cases was 38.75 % and 41.44 %, re-
spectively (Fig. 2).
Cases from Catalonia and the Basque Country sites
were used for incidence calculation (as these investiga-
tors’ patient quotas were available). Among the 898 epi-
sodes of AGE registered, 38.1 % were positive for RV.
The incidence rate of RVGE for the 5-month (Decem-
ber-April) seasonal period was 2.01 [1.81–2.24] per 100
children (Fig. 3). The higher incidence rate of RVGE was
registered in February with 3.91 (95 % CI: 3.26–4.65) per
100 children ≤ 3 years of age (Fig. 3).
Characteristics of the sample
Of the 456 patients with AGE included in the study,
417(91.5 %) were recruited in primary care centres and
39 (8.5 %) in the emergency services, and 201 (44.3 %)
patients tested positive for RV in the VIKIA test. The
proportion of RV positive cases was 66.7 % (26/39) for
cases recruited in the emergency services and 41.9 %
(175/417) among primary care cases.
Table 1 shows the epidemiological characteristics of
the sample. Mean age of the sample was 16.1 ±
8.9 months. AGE was most prevalent in children of the
6 to 24 month age-group (65.4 % of episodes). Of the
456 patients comprising the total sample, 72.1 % had not
been vaccinated against rotavirus, while 24.5 % had a
completed vaccination schedule. The children of the
sample were mostly breast-fed (83.0 %), but only 13.6 %
continued with breastfeeding at the time of the AGE epi-
sode. Previous episodes of AGE were reported in 37.9 %
of the children and 2.0 % of the children had been previ-
ously hospitalised for AGE.
Comparison of RVGE+ versus RVGE-
Tables 1 and 2 show the epidemiological and clinical
characteristics of RVGE+ and RVGE- children, re-
spectively. Age distributions of RVGE+ cases were
significantly different to RVGE- cases, being 73.1 %
and 59.2 % respectively, between 6 and 24 months of
age. When comparing the risk factors between RVGE
+ and RVGE- patients, statistically significant differ-
ences were found in the percentages of vaccination
(11.0 % vs. 41.9 %, p <0.001), breastfeeding at the
time of the episode (17.5 % vs. 10.3 %, p = 0.041),
number of previous episodes of AGE (p = 0.045), and
of those currently attending care day centres (40.2 %
vs. 51.2 %, p = 0.020).
During the previous 24 h prior to paediatrician visit, RV
infected patients presented a higher frequency of fever
(61.2 % vs. 41.7 %, p <0.001) and vomiting (69.1 % vs.
50.0 %, p <0.001), and the number of vomiting episodes
was also higher (3.0 [IQR: 2.0–5.0] vs. 2.0 [IQR: 1.0–3.0],
p = 0.004). Moreover, RVGE+ patients had a higher inci-
dence of dehydration (20.3 % vs. 7.6 %, p <0.001) and the
severity of this dehydration was also higher. RVGE+ cases
needed hydration treatment more frequently (68.3 % vs.
54.3 %, p = 0.004) than RVGE- ones.
During the whole course of the episode, RVGE+ chil-
dren presented more frequently with fever (60.1 % vs.
49.8 %, p = 0.03) and vomiting (65.0 % vs. 48.0 %, p =
0.001), and required a higher number of visits to the
emergency room (41.5 % vs. 25.0 %, p <0.001) than those
RVGE- ones. Hospital admission was also more frequent
among RVGE+ than RVGE- children (6.7 % vs. 3.3 %, p
= 0.007) (Table 2).
In families where the children were infected with RV,
the percentage of new infections among relatives was
higher (48.0 % vs. 25.1 %, p = 0.001).
January February March April December-AprilDecember
Fig. 2 Proportion of acute gastroenteritis attributable to RV from December 2014 to May 2015
Arístegui et al. BMC Infectious Diseases  (2016) 16:549 Page 5 of 12
Fig. 3 Overall incidence rate of RVGE (Catalonia and Basque Country) from December 2014 to May 2015
Table 1 Epidemiological characteristics of the overall, RV+ and RV- children and possible risk factors of RVGE
Total N = 456 n (%) RV + N = 201 n (%) RV – N = 253 n (%) p-value
Gender Male 236 (51.9) 95 (47.3) 140 (55.6) 0.079
Female 219 (48.1) 106 (52.7) 112 (44.4)
Age-groups (3-groups) 0–12 166 (36.4) 79 (39.3) 87 (34.4) 0.063
12–24 184 (40.4) 86 (42.8) 97 (38.3)
24–36 106 (23.2) 36 (17.9) 69 (27.3)
Age-groups (5-groups) 0–2 10 (2.2) 4 (2.0) 6 (2.4) 0.028
2–6 42 (9.2) 14 (7.0) 28 (11.1)
6–12 114 (25.0) 61 (30.3) 53 (20.9)
12–24 184 (40.4) 86 (42.8) 97 (38.3)
24–36 106 (23.2) 36 (17.9) 69 (27.3)
RV vaccination Complete 109 (24.5) 20 (10.0) 89 (36.6) 0.001
Partial 15 (3.4) 2 (1.0) 13 (5.3)
None 321 (72.1) 179 (89.1) 141 (58.0)
Breastfeeding Yes 376 (83.0) 171 (85.9) 204 (80.6) 0.137
Continue with breastfeeding Yes 51 (13.6) 30 (17.5) 21 (10.3) 0.041
Number of previous episodes of AGE 1 80 (52.3) 41 (67.2) 39 (42.9) 0.045
2 42 (27.5) 13 (21.3) 29 (27.5)
3 18 (11.8) 5 (8.2) 13 (11.8)
>3 13a (8.5) 2 (3.2) 10 (11.0)
Previous hospitalizations for AGE Yes 9 (2.0) 3 (1.5) 6 (2.4) 0.737
Attendance at day care center (currently) Yes 210 (46.6) 80 (40.2) 128 (51.2) 0.020
a1 missing data; RV: rotavirus; RV+: VIKIA test positive; RV-: VIKIA test negative; AGE: acute gastroenteritis
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Table 2 Clinical characteristics and consequences of AGE overall and in RV positive and RV negative
Total N = 456 n (%) RV + N = 201 n (%) RV – N = 253 n (%) p-value
Symptoms 24 h before the visit
Fever 229 (50.3) 123 (61.2) 105 (41.7) 0.001
Diarrhoea 424 (98.2) 193 (97.0) 247 (99.2) 0.147
Vomiting 249 (58.2) 132 (69.1) 116 (50.0) 0.001
Dehydration 59 (13.1) 40 (20.3) 19 (7.6) 0.001
Level of dehydrationb 0.05
A 169 (86.0) 76 (80.9) 84 (91.3)
B 12 (6.5) 10 (10.6) 2 (2.2)
C 14 (7.5) 8 (8.5) 6 (6.5)
Hydration Treatment 255 (60.6) 129 (68.3) 125 (54.3) 0.004
Relatives with similar symptoms 131 (29.3) 63 (32.1) 68 (27.3) 0.267
VIKIA test (at the visit) 411 (93.2) 180 (93.3) 229 (93.1) 0.943
Patient referral 19 (4.2) 8 (4.0) 11 (4.4) 0.837
Emergency department 6 (31.6) 1 (12.2) 5 (45.5) 0.177
Hospital 7 (87.5) 6 (54.5)
Symptoms and severity of the current AGE episode
Fever 224 (54.1) 110 (60.1) 114 (49.8) 0.03
Diarrhoea 442 (96.9) 197 (98.0) 243 (96.0) 0.230
Vomiting 249 (55.6) 130 (65.0) 118 (48.0) 0.001
Level of dehydrationb 0.051
A 302 (93.2) 138 (90.2) 162 (95.9)
B 8 (2.5) 7 (4.6) 1 (0.6)
C 14 (4.3) 8 (5.2) 6 (3.6)
Hospitalization 15 (5.0)a 10 (6.7)a 5 (3.3)a 0.007
Number of visits to the emergency department 0.006
1 93 (25.9) 55 (33.1) 38 (19.8)
2 21 (5.8) 11 (6.6) 9 (4.7)
≥ 3 4 (1.1) 3 (1.8) 1 (0.5)
Consequences of AGE
New relatives infected 157 (35.2) 95 (48.0) 62 (25.1) 0.001
Child cries more than usually 276 (61.3) 147 (73.5) 128 (51.4) 0.001
Child is distressed 303 (67.3) 153 (76.5) 149 (59.8) 0.001
Child plays less than usually 264 (59.1) 143 (71.9) 120 (48.6) 0.001
Child is more tired than usually 291 (64.7) 155 (77.5) 135 (54.2) 0.001
Level of worry of parents, mean (SD) 6.7 (2.29) 7.1 (2.10) 6.4 (2.38) 0.001
Sleep disturbances 394 (87.0) 182 (90.5) 210 (84.0) 0.040
Need of external aid 164 (36.4) 88 (44.2) 75 (30.1) 0.002
Alteration of working rhythm 135 (29.9) 78 (39.0) 57 (22.9) 0.001
Having loss of working days 95 (21.0) 50 (24.9) 45 (18.0) 0.075
Having income loss 63 (14.1) 32 (16.1) 31 (12.6) 0.295
Income loss, (euros), mean (SD) 115.1 (96.96) 141.6 (113.76) 89.5 (70.39) 0.108
Costs, (euros), mean (SD) 41.6 (33.6) 47.3 (38.2) 36.7 (28.3) 0.011
SD standard deviation
asome missing data (n = 300)
bLevel of dehydration: A = No dehydration, B = some dehydration, C = severe dehydration
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With regards to the impact of the GE episode on chil-
dren, those with RV infection cried more (73.5 % vs.
51.4 %, p <0.001), were more irritable (76.5 % vs. 59.8 % p
<0.001), played less (71.9 %% vs. 48.6 %, p < 0.001), and
were more tired than usual (77.5 % vs. 54.2 %, p <0.001)
than non-RV infected children.
Parents whose children had a RV infection were more
concerned (10-points visual scale punctuation of 7.0
[IQR: 6.0–9.0] vs. 6.0 [IQR: 5.0–8.0], p = 0.001) and re-
ported more sleep disturbances (90.5 % vs. 84.0 %, p =
0.040) than those of the non-RV infected children. As a
result, these parents have needed more external support
(44.2 % vs. 30.1 %, p = 0.002) and more modifications to
their working schedules (39.0 % vs. 22.9 %, p <0.001)
than those parents of non-RV infected children. The
additional mean cost related to the GE episode was also
higher in families whose children suffered a RV infection
(€ 47.3 [38.2] vs. € 36.7 [28.3], p = 0.011) than those
whose children were not RV infected (Table 2).
In the multivariate analysis, significant differences in
RV vaccination, fever, episodes of vomiting in the previ-
ous 24 h, and child´s behaviour (more tired) were ob-
tained (Table 3).
Discussion
This is the first multicentre study to assess the incidence
and burden of RVGE among children ≤ 3 years of age in
outpatient settings carried out in Spain. Our findings high-
light the burden and characteristics of RVGE in different
areas of the country. The overall incidence rate of RVGE
was found to be 2.01 per 100 among children less than
3 years of age, with a seasonal peak of 3.91 per 100, with
RV infection accounting for 33.89 % of acute GE episodes
in these settings. This proportion is similar to those seen in
previous European studies involving primary care settings
[6, 17, 19] and showed RV to account for a third of primary
care consultations for AGE among children. In Spain, pre-
vious studies [8, 20] carried out during 2005–2007 reported
a lower proportion (13–15 %) of AGE attributable to RV
among children examined by primary care physicians.
However, the difference in the burden of RV disease is
known to vary over time and many factors (age of the chil-
dren recruited, methods of diagnosis of RVGE, etc.) can in-
fluence these figures. The 5-months seasonal incidence rate
is in accordance with previous estimates for Spain obtained
in the REVEAL study, which reported an annual incidence
rate of 4.73 % in children < 5 years of age.
The proportion of AGE attributable to RV varied by age
and was highest in children 6–24 months of age (73.1 %).
Moreover, AGE attributable to RV affects children of
younger ages than AGE not associated to the RV, with the
subsequent clinical repercussions. This is consistent with
the results found in similar studies throughout the world
[9, 21–23]. Furthermore, this can be explained by the fact
that at < 6 months of age maternal antibodies have a pro-
tective effect, while at >24 months children may have
already developed a natural immunity due to recurrent
rotavirus infections. In this study, the peak age of 12–24
months is consistent with a European study showing the
peak of infection occurring in the second year of life [24].
As opposed to what happens in under-developed areas
where the peak occurs between 6–12 months [25]. The
early peak of RVGE in these countries may result from
early exposure to contaminated sources as well as over-
crowded homes [26]. In this study, the peak incidence of
RVGE occurred in January-February, differing slightly
from the seasonal distribution described for Spain in the
REVEAL study in which the peak incidence of RVGE was
December-January [6] and was probably related to the
lower recruitment rate at the beginning of the study.
With regards to environmental factors, it is observed
that only half of children with AGE episodes attended
day care centres (40.2 % of the RVGE+ and 51.2 % of
the RVGE- children), which contrasts with the hypoth-
esis that attending these centres may be a risk factor for
RVGE infection [27].
Rotavirus GE cases were related with a higher presence
and severity of symptoms (presence of fever, vomiting, de-
hydration) that non-RVGE [9, 28, 29]. These more severe
consequences (mainly dehydration), implies a more fre-
quent use of health care resources (physicians and emer-
gency room visits and hospitalizations) for RV infection.
Although, the emergency services were underrepresented
in our study, the proportions of RVGE+ cases in this set-
ting was considerably higher (66.7 % vs 41.9 %) compared
to the those of the primary care centres. This observation
is consistent with findings from previous studies [30].
A recent review estimated that RVGE costs the Spanish
national health system EUR 28 million a year, has a con-
siderable psychosocial impact on the family, and causes
productivity loss in two-thirds of parents (mean of 4 days)
[9]. The results of our study showed that children infected
with GE caused by RV presented with the greatest number
of infections. Also, it showed the negative effects to the
overall general condition of the children (cries more,
played less, is more irritable, more tired than usual) and to
that of the parents (more concerned, greater need of ex-
ternal help, and a greater number of disturbances to the
working rhythm); results similar to those obtained in
other studies [28, 31]. Probably, this higher impact on par-
ents in the cases of RVGE+ children is related to the more
severe symptoms observed in RV infected children and
the higher number of house members infected compared
to RVGE- cases. With regards to the loss of working days
and loss of income, unlike those reported in other studies
[9]; our study showed no significant differences although
an increase in the additional costs related to the AGE epi-
sode was observed.
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Table 3 Epidemiological and clinical differences between children with (VIKIA+) and without rotavirus. Univariate and Multivariate
analysis
Univariate analysis Multivariate analysis (N = 375)
N OR IC 95 % p-value OR CI 95 % p-value
Gender Male 453 0.080
Female 1.395 0.961–2.023 0.080
Age (months) 454 0.978 0.957–0.999 0.038 0.984 0.958–1.010 0.215
RV Vaccination Complete vaccination 444 <0.001 <0.001
Partial vaccination 0.685 0.143–3.278 0.636 0.751 0.144–3.919 0.735
No vaccination 5.649 3.316–9.625 <0.001 5.758 3.196–10.374 <0.001
Breastfeeding No 452 0.138
Yes 1.467 0.884–2.435 0.138
Attendance at day care centre No 449 0.021
Yes 0.641 0.440–0.934 0.021
Fever 24 h. befote the visit No 453 <0.001 0.018
Yes 2.208 1.512–3.223 <0.001 1.779 1.103–2.868 0.018
Number of episodes of vomiting 24 h. before the visit 423 1.246 1.138–1.363 <0.001 1.112 1.000–1.236 0.050
Number of depositions 24 h. before the visit 448 1.004 0.953–1.059 0.873
Dehydration 24 h. before the visit No 448 <0.001
Yes 3.111 1.737–5.569 <0.001
Rehydratation treatment 24 h. before the visit No 419 0.004 0.170
Yes 1.806 1.209–2.698 0.004 1.413 0.862–2.316 0.170
Fever returning at the follow-up No 412 0.037
Yes 1.520 1.026–2.252 0.037
Number of daily episodes of vomiting during the follow-up 446 1.219 1.111–1.338 <0.001
Maximum number of daily depositions during the follow-up 454 1.085 1.024–1.149 0.005
Grade of dehydration during the follow-up A 322 0.110
B 8.207 0.998–67.456 0.050
C 1.565 0.530–4.621 0.417
Hospitalization No 449 0.108
Yes 2.094 0.850–5.157 0.108
Visits general practitioner/paediatrician No 429 0.347
Yes 1.466 0.660–3.255 0.347
Visits to emergency department No 358 <0.001
Yes 2.134 1.361–3.345 <0.001
Phone consultations No 337 0.231
Yes 1.335 0.832–2.142 0.231
Child´s behaviour: Cries more No 449 <0.001
Yes 2.621 1.756–3.912 <0.001
Child´s behaviour: is more irritable No 449 <0.001
Yes 2.184 1.445–3.303 <0.001
Child´s behaviour: Plays less No 446 <0.001
Yes 2.702 1.816–4.019 <0.001
Child´s behaviour: Is more tired No 449 <0.001 0.002
Yes 2.909 1.921–4.405 <0.001 2.277 1.357–3.819 0.002
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Previous studies suggested that implementing uni-
versal vaccination could have an impact on hospital
admissions, emergency and paediatric visits related to
RVGE [9]. Our study results were in line with these
observations. These findings show evidence on the
impact of vaccination in reducing hospitalisations
[32, 33]. They also provide strong support for the
theory that the vaccination of infants against RV may
have a major impact in reducing RVGE morbidity, as
well as, in alleviating the pressure on healthcare ser-
vices due to AGE among young children in Europe.
Note that other European studies suggest a more
than 80 % reduction of hospitalizations caused by
Rotavirus in such cases where vaccination rates for
this disease are high. Finally, rotavirus gastroenteritis
has a considerable psychosocial impact on the family
and causes high levels of stress among parents [34]
and the results of the study suggest that the burden
of RVGE on children and their families could be sub-
stantially reduced by the routine rotavirus vaccination
of infants. Moreover, some studies suggest that RVGE
is a common infection in family members, parents
and caretakers of RV infected children [35–37] and a
significant deficit in diarrheal cases in older children
and adults has been related to an additional indirect
effect of vaccination [38]. Further investigations are
needed to analyze the cost-effectiveness of RV vac-
cination among children less than 3 years of age.
Strengths and limitations
The limitations of the study are those of any observa-
tional study. Only those children that were seeking
health care were included in the study, but looking at
the characteristics of the sample it is reasonable to
assume that non-included cases would have had simi-
lar traits [5]. The recruitment rate at the beginning of
the study was low (1 per 5 attended children), but
this was later increased. Other limitations were that
the patient quota of participating researchers in the
private centres of Andalusia could not be reached and
this fact limited the overall incidence rate estimation
for this autonomic community and that the emer-
gency services were underrepresented. Finally, we lim-
ited the period of the study to the season for RVGE
that extended from December to April, since asses-
sing rotavirus seasonality was not the objective of the
study. Nevertheless, the use of a common protocol
consisting of the standard data collection by the gen-
eral practitioners in the different geographical areas,
the systematic evaluation of consecutive AGE patients
from the different centres, and the laboratory con-
firmation of RVGE strengthened the results.
Conclusions
In summary, rotavirus infections make up for a substantial
proportion of AGE cases in children ≤ 3 years of age in
Spain attended at primary care consultations. RVGE as
compared with AGE due to other infectious causes is
more frequently associated with severe symptoms and in-
creased hospitalizations,. The severity of symptoms may
cause anxiety, sleep, and working rhythm disturbances in
the affected child’s parents, as well as discomfort to the
child. The routine rotavirus vaccination of infants ≤3 years
of age could considerably reduce the significant burden of
this potentially serious childhood disease.
Additional files
Additional file 1: Table S1. Parent’s questionnaire. This file is the
questionnaire administered to each child´s parent. (DOC 33 kb)
Additional file 2: Figure S1. Flow-chart of the study considering each
autonomous community. This figure represents the flow-chart of the
study detailed by the three 3 specific geographical areas of Spain
analyzed (Catalonia, Basque Country, Andalusia). (DOC 128 kb)
Table 3 Epidemiological and clinical differences between children with (VIKIA+) and without rotavirus. Univariate and Multivariate
analysis (Continued)
Impact on the parents: worried because of the symptoms No 451 0.092
Yes 3.038 0.836–11.040 0.092
Impact on the parents: Sleep disturbance No 451 0.043
Yes 1.824 1.020–3.262 0.043
Impact on the parents: Need of external aid No 448 0.002
Yes 1.839 1.246–2.715 0.002
Impact on the parents: Alteration of the working rhythm No 449 <0.001 0.264
Yes 2.154 1.429–3.245 <0.001 1.351 0.797–2.290 0.264
Impact on the parents: Loss of working days No 451 0.076
Yes 1.508 0.958–2.376 0.076
OR Odds Ratio, CI 95 % 95 % Confidence interval
Dependent variable of logistic regression: Result of the VIKIA test for RV (Positive = 1/Negative = 0)
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